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Experimental autoimmune encephalomyelitisMitochondrial dysfunction has been proposed to play a role in the neuropathology of multiple sclerosis (MS).
Previously, we reported signiﬁcant alterations in the transcription of nuclear-encoded electron transport
chain genes in MS and conﬁrmed translational alterations for components of Complexes I and III that resulted
in reductions in their activity. To more thoroughly and efﬁciently elucidate potential alterations in the
expression of mitochondrial and related proteins, we have characterized the mitochondrial proteome in
postmortem MS and control cortex using Surface-Enhanced Laser Desorption Ionization Time of Flight Mass
Spectrometry (SELDI-TOF-MS). Using principal component analysis (PCA) and hierarchical clustering
techniques we were able to analyze the differential patterns of SELDI-TOF spectra to reveal clusters of
peaks which distinguished MS from control samples. Four proteins in particular were responsible for
distinguishing disease from control. Peptide ﬁngerprint mapping unambiguously identiﬁed these differen-
tially expressed proteins. Three proteins identiﬁed are involved in respiration including cytochrome c oxidase
subunit 5b (COX5b), the brain speciﬁc isozyme of creatine kinase, and hemoglobin β-chain. The fourth protein
identiﬁed wasmyelin basic protein (MBP). We then investigated whether these alterations were consistent in
the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. We found that MBP was
similarly altered in EAE but the respiratory proteins were not. These data indicate that while the EAE mouse
model maymimic aspects of MS neuropathology which result from inﬂammatory demyelinating events, there
is another distinct mechanism involved in mitochondrial dysfunction in gray matter in MS which is not
modeled in EAE.er Desorption Ionization Time
ent analysis; NAGM, normal
, experimental autoimmune
tochrome c oxidase subunit 5b
ciences, Kent State University,
330 672 9391.
).
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Multiple sclerosis (MS) is an inﬂammatory neurodegenerative
disease of the central nervous system resulting in progressive physical
and cognitive disability. In the MS brain, white matter lesions are a
hallmark of the disease; however, cortical gray matter lesion load has
been found to be extensive [1] and damage to neurons and axons
correlates with progression and cognitive impairment [2–4]. Several
studies have implicated mitochondrial dysfunction as a possible
mechanism in the development of MS related neuropathology.
Nuclear magnetic resonance spectroscopy has identiﬁed decreases
in the neuronal mitochondrial metabolite N-acetyl aspartate (NAA) in
MS brain and decreases in NAA appears to precede neuronal atrophy,indicating that dysfunctional mitochondria may precede neurode-
generation [5,6]. Mitochondrial dysfunction has also been implicated
in disease pathology in the experimental autoimmune encephalomy-
elitis (EAE) mouse model of MS [7]. It has been reported that
increased nitration of electron transport chain components leads to
decreased mitochondrial activity in EAE [8] and that cyclophilin D, a
modulator of the mitochondrial permeability transition pore, is
protective [9]. Similarly, analyses of postmortem MS white matter
have identiﬁed alterations to mitochondrial enzyme activity and
damage to mitochondrial DNA in lesions [10–12]. Other studies have
demonstrated defects in mitochondrial electron transport gene
expression and function in normal appearing gray matter (NAGM)
in postmortem MS cortex [13,14]. These studies have identiﬁed
transcriptional changes in important mitochondrial genes; however,
translational or post-translational alterations in a multitude of other
proteins may also impact mitochondrial function and energy
production. Therefore, in the current report, we have applied Surface
Enhanced Laser Desorption and Ionization time-of-ﬂight mass
spectrometry (SELDI-TOF-MS) to mitochondrial fractions derived
from MS cortex to obtain a more complete understanding of protein
expression changes that could contribute to the mechanisms of
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MS brain tissue may provide new insights into the pathogenesis and
etiology of the disease. Previous proteomic analyses of MS tissue have
focused on white matter, lesioned tissue, and cerebrospinal ﬂuid
(CSF) [15–23]. However, there is evidence from magnetic resonance
imaging studies that the mechanisms involved in tissue damage are
different in gray matter and white matter in MS [24,25]. Therefore
studies detailing protein differential expression in normal appearing
gray matter are necessary to provide additional insight into disease
manifestation and progression as it relates to the neurodegenerative
component of MS pathology.
2. Materials and methods
2.1. Tissue preparation and protein extraction
Reagents used in the preparation of all buffers were obtained from
Sigma-Aldrich (St. Louis, MO). Brains were obtained from The Rocky
Mountain MS Center Tissue Bank (Englewood, CO), the Brain and
Spinal Fluid Resource Center (UCLA) and The Kathleen Price Bryan
Brain Bank (Durham, NC) under IRB protocol. Tissue was obtained by
rapid autopsy and frozen at−70 °C. This study includes two cohorts,
each consisting of four controls and four secondary progressive
multiple sclerosis (SPMS) donors. Tissue from each cohort was
homogenized on separate dates using identical protocols. MS and
control brains have been matched primarily for brain region (parietal,
Brodmann areas 1–3, and frontal cortex, Brodmann area 9), and also
for age, sex, and post mortem interval (PMI) as closely as possible.
Frozen sections, 30 μm thick, from adjacent sides of the tissue blocks
were immunostained for myelin proteolipid protein (PLP) to ensure
the absence of demyelinated lesions as previously described [26].
Donor demographics are described in Table 1. Eight controls and eight
MS donors were used for the differential expression proteomic
analyses while one additional control (C9) and MS donor (MS9)
were used in western blotting for conﬁrmation.
EAE was induced in C57Bl/6 mice by subcutaneous injection of
MOG35–55 as previously described [27]. EAE brains and brains from
control littermates were prepared at The University of Calgary and
sent frozen to Kent State University for analysis by Western blotting
and SELDI-TOF-MS. Protein was isolated from whole brains and from
cortex for Western analyses. EAE-afﬂicted mice were at peak clinical
severity (Grade 4 of the 5-point scale) when sacriﬁced.
For postmortem human tissue, approximately 250 mg tissue from
frozen blocks was carefully excised excluding white matter. TissueTable 1
Donor description.
Sample Age (years) Sex PMI (hours) Brain region
C1 57 M 4.5 Fr
C2 87 M 6.5 Pa
C3 72 F 30 Pa
C4 75 M 19 Pa
C5 80 M 14 Fr
C6 65 M 3.5 Pa
C7 86 F NA Pa
C8 73 F 12 Fr
C9 74 F 5 Fr
MS1 48 M 4 Fr
MS2 30 M 5 Pa
MS3 62 F 6 Pa
MS4 36 F 3 Pa
MS5 30 M 5 Fr
MS6 78 M 15.5 Pa
MS7 81 F 11.8 Pa
MS8 52 F 20.6 Fr
MS9 51 F 5.25 Fr
C—control donors; MS—MS donors; M—male; F—female; Fr—frontal cortex; Pa—parietal
cortex; NA—not available.was homogenized using a Wheaton homogenizer with a Teﬂon®
pestle in whole cell homogenization buffer (20 mM KCl, 3 mMMgCl2,
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
pH 7.9, 0.5% NP-40, 5% glycerol with protease inhibitors (P2714,
Sigma-Aldrich, St. Louis, MO) in forty strokes. The homogenate was
centrifuged for 10 minutes at 500g at 4 °C. The supernatant was
removed and centrifuged at 10,000 g for 30 minutes at 4 °C. The pellet
containing the mitochondrially enriched fractions was further
puriﬁed by washing twice in 20 mM phosphate buffered saline
(PBS), pH 7.4. The mitochondrial pellet was lysed in mitochondrial
lysis buffer (50 mMTris, 7 M urea, 3% CHAPSwith protease inhibitors)
by vortexing for 1 minute and then incubating for 20 minutes at room
temperature. The mitochondrial lysate was centrifuged for 10 min-
utes at 10,000g at 4 °C. A modiﬁed Lowry assay was used to quantify
the supernatant protein concentration. All samples were stored at
−80 °C until further analysis.
2.2. Immunoﬂuorescent staining
Frozen tissue blocks from postmortemMS and control brains were
ﬁxed in 4% paraformaldehyde for 24 hours and washed in PBS
(2×24 hours). Fixed tissue blocks were sliced 75 μm thick perpen-
dicular to the outer edge of the cortex (to include all cell layers) on a
media cooled vibratome. Sections were stored in PBS in multiwell
plates at 4 °C in a humidiﬁed chamber until subjected to the staining
procedure. Thereafter, free-ﬂoating sections were incubated in goat
anti-hemoglobin (1:100, Thermo Scientiﬁc, Rockford, IL) and mouse
anti-neuroﬁlament (1:500, SMI-32, Covance, Princeton, NJ) antibo-
dies in PBS, 5% triton-X 100, 3% normal donkey serum for 24 hours.
After 3 washes in PBS (10 minutes each) the tissue was incubated in
donkey anti-mouse Alexa 488 (1:250, A-11055 Invitrogen, Carlsbad,
CA) and donkey anti-goat Alexa 546 (1:250, A-11056 Invitrogen,
Carlsbad, CA) in PBS for 12 hours. Following three 10-minute washes
in PBS, the sections were incubated in 50 mM ammonium acetate,
10 mM cupric sulfate for 30 minutes to quench lipofuscin auto-
ﬂuorescence. Sections were next washed three times in PBS
(10 minutes each), placed below coverslips under Vectashield®
mounting media (Invitrogen, Carlsbad, CA), sealed with clear nail
polish, and refrigerated until microscopically imaged. Images were
acquired using an Olympus FV500 confocal microscope equippedwith
four lasers (HeCd 442 nm, Ar 488 nm and 514 nm, HeNe 543 nm and
HeNe 633 nm) and a 60× oil objective. Microscopic ﬁelds were
acquired that clearly contained pyramidal cells as indicated by
neuroﬁlament staining. Green and red ﬂuorescence image stacks
were captured sequentially to prevent any channel bleed through, and
spanned the physical section. All images were acquired with isometric
voxels at a resolution of 0.42 μm per pixel. The image stacks were z-
projected using ImageJ (NIH, Bethesda, MD) and channels merged to
show co-localized signal within pyramidal cells.
2.3. Western blotting
Mitochondrially enriched or cytoplasmic samples were separated
on NuPage® 4–12% Tris gel (Invitrogen, Carlsbad, CA) for 35 minutes
at 200 V, transferred to nitrocellulose paper for 1 hour at 45 V and
incubated with the appropriate antibodies, either mouse MBP
(AbCam, Cambridge, MA), human MBP (Chemicon, Temecula, CA),
creatine kinase (AbCam, Cambridge, MA), COX5b (Invitrogen,
Carlsbad, CA), hemoglobin (Thermo Scientiﬁc, Rockford, IL), or
neuroﬁlament (Chemicon, Temecula, CA). The blots were exposed
to the corresponding secondary horseradish peroxidase conjugated
secondary IgG (sc2005-mouse/sc2001-rabbit Santa Cruz Biotechnol-
ogy, Inc. Santa Cruz, CA) and visualized using enhanced chemilumi-
nesence reagents (sc2048, Santa Cruz Biotechnology, Inc. Santa Cruz,
CA). Densitometry was performed using ImageJ (NIH, Bethesda, MD)
from three MS and control comparisons or EAE and control brain
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standardized with antibodies against either Complex IV subunit 2
(COX2, 1:2000, MS405, Mitosciences, Eugene, OR), a mitochondrially
encoded protein, or the Complex II SDHA subunit (Molecular Probes,
Eugene, OR) for mitochondrial fractions, and GAPDH (Chemicon,
Temecula, CA) for cytoplasmic fractions. A Student's t-test was
performed to determine statistical signiﬁcance.
2.4. Ion exchange fractionation
The mitochondrial enriched protein extracts were further fraction-
ated using ion exchange chromatography in a spin column format
(column-UFC30HV00; centrifuge tube-UFC3000TB Millipore, Billerica,
MA). Samples (100 μg each)were equilibratedusing buffer A (9 MUrea,
2% CHAPS in 50 mM Tris HCl pH 9.0) and incubated for 20 minutes at
room temperature. Buffer B (Buffer A diluted 1 part to 8 parts 50 mM
Tris HCl, pH9.0)was used to dilute all samples to 200 μL and then stored
on ice while the remaining samples were prepared (30 minutes
maximum). The quaternary ammonium anion exchange beads (Q
ceramic HyperD F, Pall Biosepra, New York, NY)were equilibrated three
times in buffer B. The samples were loaded onto the column/tube and
mixed in an end to end fashion for 30 minutes at room temperature.
After this initial incubation, the samples were centrifuged for 1 minute
at 1000g. This eluate was the ﬂow through fraction. The column was
removed from the centrifuge tube andplaced in thenext centrifuge tube
labeled according to the wash buffer. The pH 9 elution buffer (50 mM
TrisHCl, pH9.0, 0.1%octyl glucopyranoside (OGP), 200 μL)was added to
the column and mixed in an end to end fashion for 10 minutes, then
centrifuged as before. This process was repeated for each buffer at pH
7.0, 5.0, 4.0, and 3.0, and a ﬁnal organic solvent elution, yielding six
fractions with pI ranges of greater than 9.0 in fraction 1, 7.0–9.0 in
fraction 2, 5.0–7.0 in fraction 3, 4.0–5.0 in fraction4, 3.0–4.0 in fraction5,
and less than 3.0 in fraction 6, respectively. Speciﬁc buffer compositions
were as follows: pH 7.0 elution buffer; 50 mMHEPES pH 7.0, 0.1% OGP,
pH 5.0 elution buffer; 100 mM sodium acetate pH 5.0, 0.1% OGP, pH 4.0
elution buffer; 100 mM sodium acetate pH 4.0, 0.1% OGP, pH 3.0 elution
buffer; 50 mM sodium acetate pH 3.0, 0.1% OGP; organic elution buffer;
33.3% isopropyl alcohol (IPA), 16.7% acetonitrile (ACN), 0.1% triﬂuor-
oacetic acid (TFA). All protein solutions were stored on dry ice until
return to the−80 °C freezer.
2.5. SELDI-TOF-MS acquisition
All samples were mixed with a saturated α-cyano-4-hydroxycin-
namic acid matrix solution consisting of 50% ACN and 0.5% TFA by
volume with 0.6% OGP by weight in a 1:5 dilution. Each matrix diluted
sample (1 μL) was applied to a spot on an NP20 Proteinchip® (normal
phase chromatographic surface, Ciphergen Biosystems, Fremont, CA)
chip in a randomizedmanner.Mass spectrawere acquiredwith amodel
PBSIIc SELDI-TOF mass spectrometer manufactured by Ciphergen
Biosystems (Fremont, CA). The optimal sensitivity and laser intensity
were established on a location not used in transient averaging. These
values were then used to develop a spot protocol. This same protocol
was applied to all chips. Data were acquired at a digitizer rate of
250.0 MHz in positive ion mode with a chamber vacuum of less than
5×10−07 Torr. The source voltage was 20 kV and the detector voltage
was2700 V.A total of 65 transientswere averaged for eachspectrum.All
spectral processing (smoothing and baseline subtraction) was per-
formedwith Proteinchip 3.1 Software (Ciphergen Biosystems, Fremont,
CA). Spectrawere calibrated externally over the appropriatemass range
using at least three of the following standards: recombinant Hirudin
BHVK (6,964 Da), bovine cytochrome c (12,230 Da) equine cardiac
myoglobin (16,952 Da), bovine RBC carbonic anhydrase (29,024 Da)
and Saccharomyces cerevisae enolase (46,670 Da). In order to make
appropriate comparisons, all spectra were normalized against the total
ion current [15].2.6. Data analysis
Manual peak picking, using a signal to noise ratio of greater than
4.0, allowed for unbiased peak selection. Automatic peak detection in
Ciphergen Express often neglects those features which appear as
shoulders on larger peaks [28] and consequently manual peak
selection across all spectra of the same fraction provided a more
accurate assessment of the spectral features. Criterion for the
selection of peaks across the entire data set required peak occurrence
in 25% of the spectra with a signal to noise ratio greater than 4.0. Peak
occurrence percentages were selected based upon the expected
absence of some peaks from either the control or the MS group. Peaks
selected for further evaluation and validation had a signal to noise
ratio of greater than 3.0 and were present in the overexpressed
sample group (control or MS). All statistical calculations were done
with Ciphergen® Express software (Ciphergen Biosystems, Fremont,
CA). Univariate analysis included the non-parametric Mann–Whitney
test. Applicable multivariate techniques included principal compo-
nent analysis (PCA) and hierarchical clustering [29]. Peaks considered
differentially expressedwere those altered by at least 1.8 fold, pb0.05.
2.7. Immunoprecipitation
Anti-nitrotyrosine antibody (05-233 Millipore, Billerica, MA) was
crosslinked to Protein G agarose beads using the Pierce Seize X kit
according to manufacturer's instructions. Brieﬂy, Protein A agarose
beads were used to preclear mitochondrially enriched proteins.
Protein G beads were covalently crosslinked to the anti-nitrotyrosine
antibody using disuccinimidyl suberate and washed to remove any
unreacted molecules. The beads were then incubated with mito-
chondrially enriched NAGM protein and any unbound proteins were
removed by washing. The nitrated proteins were then eluted from the
beads using a low pH wash. The eluant was then separated using pre-
cast Bis-Tris gels (Invitrogen, Carlsbad, CA), stained with blue silver
[30] and destained in reverse osmosis water. Bands of interest (those
increased in MS) were excised, dehydrated and sent to the University
of Pittsburgh Genomics and Proteomics Core Facility for trypsin
digestion and peptide ﬁngerprint mapping.
2.8. Antibody pull down conﬁrmation
An antibody against COX5b (Proteintech Group, Chicago, IL, PN
11418-2-AP) were derivatized to 3 μm diameter carboxylated
polystyrene microspheres (Polysciences PN 09850) using a modiﬁed
carbodiimide method [31]. Brieﬂy, the beads were washed in 50 mM
MES (2-(N-morpholino)ethanesulfonic acid, Sigma PN M8250) twice.
A 200 mg/mL solution of EDC (N-Ethyl-N′-(3-dimethylaminopropyl)
carbodiimide hydrochloride Fluka PN-03449) in 50 mM MES was
prepared. The washed beads (100 μL) were incubated with the EDC
solution such that the ﬁnal concentration was 2 mg/mL for approx-
imately 2 minutes in a vortexer set on low speed. 200 μg of
mitochondrially enriched NAGM protein was added to 500 μL of the
bead slurry. Protein and beads were incubated with constant mixing
at room temperature for 3 hours. Beads were washed in 10 mM Tris
pH 8.0 0.5%BSA twice. Beads were stored in 150 μL 10 mM Tris pH 8.0
0.5%BSA at 4 °C. Bright ﬁeld microscopy was used to conﬁrm low self-
aggregation and antigen-antibody activity of conjugated beads.
Mitochondrial protein extracts from speciﬁc ion exchange fractions
(2.5 μL) were incubated with bead solution (2.0 μL) in 10 mM Tris pH
8.0 0.5%BSA to aﬁnal volumeof 10 μL for 1 hourwith constantmixing at
roomtemperature. Solutions frombothbefore andafterbead incubation
were diluted 1/10 in a saturated α-cyano-4-hydroxycinnamic acid
(CHCA; Sigma PN 145505-5g) aqueous solution consisting of 50% ACN
(Fisher PN A996-4), 0.6% OGP (Sigma PN O8001-5g) and 0.5% TFA (JT
Baker PN9470-00). These solutions were randomly spotted onto an NP-
20 Proteinchip® at 0.5 μL, air-dried and repeated.
Table 2
SELDI differential protein expression.
Cohort Fraction pI
range
Mann–Whitney p
value
m/z Theoretical
pI
Theoretical
MW
fold UniProt
Accession
Entry name Probability MASCOT
score
Peptides
detected
Sequence
coverage
1 5–7 0.05 10600 6.3 10613 -1.9 P10606 COX5b 3.70E-07 20.2 2 12.24
1a 5–7 0.009 15940 11.3 21493 +2.0 P02686-3 MBP1 4.34E-07 80.2 10 39.59
1a 5–7 0.009 15940 11.1 20246 +2.0 P02686-4 MBP2 4.34E-07 80.2 10 41.94
1a 5–7 0.009 15940 11.4 18591 +2.0 P02686-5 MBP3 4.34E-07 80.2 10 45.61
1a 5–7 0.009 15940 11.1 17343 +2.0 P02686-6 MBP4 4.34E-07 80.2 10 48.75
2 4–5 0.021 16012 6.8 15867 +2.6 P68871 Hbb 9.28E-05 60.2 6 51.37
2 b 3 0.021 42700 5.3 42513 +2.0 P12277 Creatine
Kinase B
1.89E-05 70.3 7 27.11
a Human MBP has 7 isoforms. All ten peptides detected by MS/MS are present in the isoforms listed.
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Individual ion exchange fractions were puriﬁed by gel electropho-
resis on 16% acrylamide Tris glycine gels at 200 V for 45 minutes [32].
The gels were stained with Coomassie blue [33] and gel plugs of
interest were removed. The gel plugs were destained [34], dehydrated
and stored in 1% acetic acid prior to trypsin digestion and peptide
ﬁngerprint mapping. Trypsin digestion followed by HPLC-ESI-MS/MS
on an LCQ Deca XPmass spectrometer (ThermoFinnigan, San Jose, CA)
was performed at the Genomics and Proteomics Core Laboratories at
the University of Pittsburgh.Fig. 1. Multivariate analysis of cohort 1, fractions 3 and 6 and cohort 2 fraction 6 using pri
hierarchical clustering and principal component score scatter plots show the segregation of M
analysis. Panel C: cohort 2 fraction 6 analysis. Peaks identiﬁed by peptide ﬁngerprint mapp3. Results
3.1. Mitochondrial protein differential expression in postmortem MS
cortex
Donor demographics are described in Table 1. Mitochondrial
samples from either parietal or frontal cortex were obtained from
NAGM as conﬁrmed using PLP staining. Analysis of the mitochondrial
fractions was divided into two separate groups or cohorts due to
tissue sample availability at study onset. The ﬁrst cohort of samples
consisted of mitochondrial fractions obtained from four control andncipal component analysis and hierarchical clustering. Multivariate analyses including
S and control samples. Panel A: cohort 1 fraction 3 analysis. Panel B: cohort 1 Fraction 6
ing are indicated with asterisks.
Fig. 1 (continued).
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became available the analysis was extended to incorporate the second
group, cohort 2, which also consisted of mitochondrial fractions
derived from four controls and fourMS brain slices (C5–8 andMS5–8).
The mitochondrial fractions were separated by ion-exchange frac-
tionation and analyzed by SELDI-TOF-MS. Mass spectra were acquired
from fractions with pI values between 9 and 3 and revealed multiple
peaks. The Mann–Whitney test was used to identify peaks with
signiﬁcant differences in peak intensities. Filtering the data for
proteins altered by at least 1.8 fold at the 0.05 signiﬁcance level we
identiﬁed nineteen peaks which were differentially expressed (see
Supplemental Data, Table1). Cohort 1 contained twelve differentially
expressed peaks, with ﬁve of these peaks from fraction 3 (pI 5.0–7.0)
and ﬁve from fraction 6 (pIb3), and cohort 2 contained seven
differentially expressed peaks, three of which originated in fraction 6
(pIb3). These fractions were selected for peptide ﬁngerprint mapping
and further investigation. Fractions 4 (pI 4.0–5.0) and 6 from cohort 2
were also selected for further puriﬁcation and peptide ﬁngerprint
mapping. Table 2 describes the identiﬁed differentially expressed
peaks from both data sets listing fold change,Mann–Whitney p values,
theoretical isoelectric point, theoretical molecular weight, cohort,
mass to charge ratio (m/z) and peptide ﬁngerprint mapping results.
3.2. Analysis of proteomic data with multivariate statistics
The application of hierarchical clustering to differential protein
expression data identiﬁes elements which may be linked in their
occurrence. This unsupervised classiﬁcation method can be used to
identify and validate those biomarkers responsible for speciﬁc
patterns and plays an essential role in current disease investiga-
tions. Since it is unlikely that one speciﬁc peak is responsible for the
differential expression between control and MS NAGM mitochond-rially-enriched proteins, a technique which detects correlated sets
of variables is needed to analyze this data. In this research, a
modiﬁed Pearson product–moment correlation coefﬁcient was
employed as a distance measure and the average linkage method
was used to perform a hierarchical cluster analysis of protein
expression and compute a dendrogram. Nodes of the dendrogram
join the most similar objects and the relative length of the branches
is indirectly proportional to the similarity of those objects. The most
signiﬁcant feature in the hierarchical clustering analysis is the
segregation of control and MS donors by disease state (fractions 3
and 6 from cohort 1 and fraction 6 from cohort 2 shown in Fig. 1
panels A, B, and C). Other fractions in this data set have only one or
two differentially expressed peaks and therefore are not sufﬁciently
complex to warrant the use of multivariate methods such as
hierarchical clustering. Fraction 3 of cohort 1 contains two distinct
nodes (Fig. 1, panel A). The short length of the branches indicates
that the peak intensities of the proteins in each node are highly
correlated, suggesting a potential relationship between the peaks in
each node. The highly correlated peaks of the upper node, contain-
ing peaks at 10.7, 10.6, 10.2, 10.1 and 9.9 kDa, have a correlation
coefﬁcient greater than 0.85. The lower node, containing peaks at
15.9, 15.8, 8.0, and 7.9 kDa, has a correlation coefﬁcient greater than
0.94. Of the four peaks, three were differentially expressed at the
95% conﬁdence level, with p values of 0.009, 0.076, 0.028 and 0.028,
respectively. Fraction 6 of cohort 1 (Fig. 1, panel B) also shows
several highly correlated nodes. The upper middle node containing
peaks at 22.9, 22.7, 11.5, 23.7, and 11.4 kDa has a correlation
coefﬁcient greater than 0.85, while the correlation coefﬁcient of the
lower middle node consisting of peaks at 9.8, 9.7, 12.6, 12.5 and
17.2 kDa is greater than 0.92. The linear correlation of the data
combined with signiﬁcant p values of 0.076, 0.028, 0.028, 0.016, and
0.076, respectively, indicate a group of possible biomarkers. Fraction
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nodes (Fig. 1, panel C).
Principal component analysis (PCA) is a common technique used
in the analysis of large data sets and uses computational methods for
pattern recognition [35]. Mathematically, in this particular analysis, a
PC is a linear combination of peaks from all samples included in the
analysis. The contribution of a speciﬁc PC to a sample's variability is
indicated by the sample score. Each sample has a single unique score
from each PC. The ﬁrst PC accounts for the greatest variability in the
data set with each subsequent PC accounting for decreasing amounts
of variability. Therefore, the ﬁrst several PCs will reveal which variable
contributes the most to the differences between the populations and
the sample speciﬁc scores will relate that variability to each sample.
Applying PCA to this research enables the identiﬁcation of key
proteins which may be responsible for the differences between
control and disease states.We used this particular analysis to generate
two dimensional scatter plots of the principal component (PC) scores
to aid in the visualization of the data reduction process. Variables with
similar scores for a speciﬁc PC will segregate together in a scatter plot,
allowing the identiﬁcation of similar variables. Because PCs are
uncorrelated by deﬁnition [36], this process can be used to verify
those factors which independently inﬂuence the data segregation. Fig.
1, panels A, B, and C display PC scatter plots of PC1 and PC2. Notice the
segregation of the data into MS and control sample groups in each
fraction. This technique also conﬁrmed that other parameters such asFig. 2. Proteomic differential expression of identiﬁed proteins. SELDI-TOF mass spectra show
as hemoglobin β chain, panel B: The 42 kDa peak was identiﬁed as creatine kinase type B
identiﬁed as MBP. Mass spectra of mitochondrial samples outlined in red are control sampbrain region, gender, age or PMI were not responsible for data
segregation. For all controlled variables, PCA veriﬁed that disease state
was the only donor characteristic responsible for sample segregation.
3.3. Identiﬁcation and conﬁrmation of differentially expressed proteins in
MS cortex
The unambiguous identiﬁcation of speciﬁc differentially expressed
peaks in cohort 1 by peptide ﬁngerprint mapping was complicated by
the low resolution of one dimensional gel electrophoresis and the
complex mixture of analytes in the 10 kDa and 16 kDa regions. Each
band contained at least two protein species as evidenced by the SELDI-
TOF mass spectra. Regardless, the entire band of each sample was
excised and submitted for peptide ﬁngerprint mapping on a
ThermoFinnigan LCQ Deca XP. Table 2 lists the most probable
identiﬁcations with Mascot scores, number of peptides, sequence
coverage, probabilities and protein characteristics. The list of matches
in the database for the 10 kDa protein fragment included cytochrome c
oxidase subunit 5b (COX5b) (UniProt accession number P10606), an
electron transport chain subunit of cytochrome c oxidase (Complex IV)
with a Mascot score of 20.2 from two peptides detected and 12.24 %
sequence coverage. The 15.9 kDa peak in fraction 3 was identiﬁed as
myelin basic protein (MBP) (UniProt accession number P02686) with a
Mascot score of 80.21 from 10 peptideswith a sequence coverage range
of 25.7% for isoform1 to over 49% for isoform6 (see Table 2) and almosting the differential expression of a set of peaks. Panel A: The 16 kDa peak was identiﬁed
, panel C: The 10.6 kDa peak was identiﬁed as COX5b, panel D: The 16 kDa peak was
les and those outlined in blue are MS samples.
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The process and protease leading to this particular differentially
expressed MBP fragment is currently under investigation.
In cohort 2, proteins from fraction 4 and 6 were puriﬁed by
electrophoresis and bands were removed at 16 kDa and 42 kDa,
respectively. The protein at 42 kDa was identiﬁed as creatine kinase
type B (UniProt accession number P12277)with aMascot score of 70.26
from seven peptides with a sequence coverage of 27.11%. The peak at
16 kDa was identiﬁed as hemoglobin β-chain (UniProt accession
number P68871) with a Mascot score of 60.25 from six peptides and
a sequence coverage of 51.37%. The SELDI-TOF mass spectra for these
four proteins are shown in Fig. 2, panels A–D, and demonstrates the
overexpression of hemoglobin β, MBP, and creatine kinase B, and
decreased expression of COX5b in MS relative to controls.
Conﬁrmation of the identiﬁcation of the peak at 10.6 kDa as COX5b
was obtained by employing COX5b antibody labeled beads. SELDI-
TOF-MS spectra acquired both before and after protein solutions were
exposed to this COX5b antibody conﬁrmed that the differentially
expressed peak at 10.6 kDa was COX5b as shown in Fig. 3A. Relative
peak intensity ratios were used to determine which peak resultedFig. 3. Conﬁrmation of the identity of differentially expressed proteins. A. Mitochondrially en
beads. Aliquots analyzed by SELDI-TOF-MS before and after incubation conﬁrm the identity o
for these spectra. B. Representative western blot demonstrating the relative purity of t
mitochondrial (mito) fractions isolated fromMS and control cortex, run side by side and blott
to the mitochondrial encoded COX2 protein. Arrows denote multiple NF immunoreactive pr
MBP, hemoglobin β (Hbb), and creatine kinase (CKB) and decreased COX5b inmitochondrial
EAEmouse brain while CKB, Hbb, and COX5bwere not similarly altered in EAE andMS. To con
II (CII) or COX2. D. Representative western blots of hemoglobin β (Hbb) and creatine kinase
and control mouse brains or cortex with GAPDH as a loading control. E. Quantitation was d
cortex. Data is expressed as percent of control for MS and EAE samples and densitometry
cytoplasmic fractions. Error bars represent SEM. *p≤0.05.from COX5b. The 10.1 kDa peak was veriﬁed as unchanged before and
after spectra by one way ANOVA and was therefore used as the
normalization peak to determine which peak intensity changed as a
result of exposure to the COX5b IgG beads. Representative spectra
from one of three trials are shown in Fig. 3A. Only the peak at 10.6 kDa
demonstrated a change in relative peak height. This molecular weight
corresponds to the mass of COX5b after signal peptide cleavage.
We then performed western blotting experiments to conﬁrm the
protein expression differences identiﬁed by SELDI-MS as shown in Fig.
3. In order to demonstrate the purity of our mitochondrial
fractionation procedure, we performed western blots for expression
of a neuronal marker, neuroﬁlament, and the mitochondrial encoded
protein cytochrome oxidase subunit II (COX2), in MS and control
cytoplasmic and mitochondrial fractions (Fig. 3B). The altered
expression of proteins identiﬁed in cohort 1 and in cohort 2, including
MBP, COX5b, creatine kinase B (CKB) and the hemoglobin-β chain
(Hbb), were conﬁrmed by western blotting in mitochondrial fractions
(Fig. 3C and D). While these proteins were not found to be
signiﬁcantly altered in both cohorts by SELDI-TOF-MS, quantitation
of western blotting experiments conﬁrmed a signiﬁcant decrease inriched protein solutions were incubated with an antibody to COX5b covalently bound to
f the mass spectral peak at 10.6 kDa as COX5b. The box highlights the region of interest
he cellular fractionation. Western blots were performed on cytoplasmic (cyto) and
ed with an antibody to the neuron speciﬁc protein, neuroﬁlament (NF), and an antibody
oteins present in cytoplasmic fractions. C. Representative western blots show increased
fractions isolated fromMS cortex. Increased expression of MBPwas also observed in the
trol for protein loading, western blots were reprobedwith antibodies to either Complex
B (CKB) in cytoplasmic fractions isolated from MS and control cortex and also from EAE
one for MBP, COX5b, Hbb, and CKB expression for MS and control samples and for EAE
was standardized to either CII or COX2 for mitochondrial fractions or to GAPDH for
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kinase B expression in mitochondrial fractions from samples across
both cohorts 1 and 2 and in additional samples (C9 andMS9) (Fig. 3E).
One control sample not included in the SELDI analysis but which was
analyzed by western blot, C9, contained consistently increased
mitochondrial content as indicated by the increase in COX2
expression (Fig. 3C). MS samples still expressed increased levels of
creatine kinase B relative to this control sample in spite of this
increase in mitochondria. Further, COX5b expressionwas signiﬁcantly
decreased in MS samples even when C9 was not included in the
analysis. COX5b and MBP were only expressed in mitochondrial
fractions. Hemoglobin and creatine kinase B were detected in both
mitochondrial and cytoplasmic fractions, but were only signiﬁcantly
increased in mitochondrial fractions in MS. Western blots were also
performed for these proteins in cytoplasmic and mitochondrial
fractions isolated from either whole brain or cortex from EAE and
control mice. Representative western blots are shown in Fig. 3C and D
and quantitation in Fig. 3E shows that only increased MBP expression
is modeled in the EAE mouse. We did observe more than one isoform
of MBP increased (two bands ~18–20 kDa) in the EAE mitochondrial
fractions rather than the one isoform increased in humanMS tissue at
~18 kDa (Fig. 3C).
Further, we localized hemoglobin expression to neuronal cell
bodies in MS postmortem tissue by immunoﬂuorescent staining with
antibodies to hemoglobin (red ﬂuorescence) and neuroﬁlament
(green ﬂuorescence) as shown in Fig. 4. We observed intense
hemoglobin staining in pyramidal neurons in MS cortex supporting
our SELDI-TOF data indicating increased expression of hemoglobin in
MS samples.
3.4. Increased nitrotyrosine modiﬁed proteins in MS
The detection of increased nitrated proteins in MS mitochondrial
fractions was performed by immunoprecipitation with an antibody to
nitrotyrosine. Eluates from the nitrotyrosine immunoprecipitation of
control and MS samples were puriﬁed using one dimensional gel
electrophoresis and differentially stained bands which were increased
in intensity in the MS mitochondrial fraction between 20–25 kDa and
40–45 kDa were excised. Nitrated proteins identiﬁed using peptide
ﬁngerprint mapping are shown in Table 3. Identiﬁed in the bands
exhibiting increased nitrotyrosine immunoreactivity in MS were the
mitochondrial encoded catalytic subunit of Complex IV of the electron
transport chain, cytochrome c oxidase subunit 2 (COX2), two subunits
of Complex I (NDUA8 and NDUV2), a subunit of Complex III (UQCR2),
2′, 3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase), beta actin
(ACTB), Creatine kinase B (CKB), and MBP. Several splice variants of
MBP have isoforms in the 20 kDa range. Ten peptides from MBP
isoforms 3 and 5 (MBP1 and MBP3) were detected and the protein
sequence coverage was calculated at 39.1% and 45.0%, respectively
(see Table 3).
4. Discussion
In this study, we examined peaks in 96 SELDI-TOF mass spectra
(six fractions from sixteen brain samples). Each mass spectrum was
represented by over 65,000 data points. To decrease the complexity
associated with such a large data set, we reduced the number of
variables using principal component analysis and generated PC score
scatter plots to more easily visualize the segregation of samples
derived from MS cortex compared to those obtained from controls. In
our ﬁrst group (cohort 1), using PCA, we analyzed mitochondrial
proteins eluted in fraction 3 and determined that the ﬁrst two PCs
accounted for 80% of the variability in the data set and allowed for
segregation of samples obtained from MS or control cortex into two
distinct groups with respect to the presence or absence of disease. The
ability to separate disease from control suggests that the presenceand/or absence of speciﬁc groups of peaks correlates with disease
expression and that these peaks may be important in elucidating
biological processes that are responsible for disease etiology or
progression. In addition, we found that of the proteins separated out
from fraction 3 of our ﬁrst cohort, the peaks in the 10 kDa and 16 kDa
range contributed the greatest amount to the separation of MS from
control donors. The lack of 10 kDa peaks and excess of the 16 kDa
peak is most prominent in MS donors. Therefore the proteins within
these peaks were selected for identiﬁcation by peptide ﬁngerprint
mapping.
The peak at 16 kDa was identiﬁed by peptide ﬁngerprint mapping
as MBP, a component of myelin. This was an unexpected result and
one that was consistent in mitochondrial fractions from both controls
and MS donors. MBP is a very basic protein which is normally
associated with membranes and it is possible that MBP released from
myelin during tissue homogenization was bound adventitiously to
mitochondrial membranes and remained in the mitochondrial
fraction even after the washing steps. However, we consistently
found increased levels of MBP associated with MS fractions and its
presence is an important distinguishing factor separating controls
from MS as determined in our principal component analysis. Other
proteomic studies of mouse brain have also shown mitochondrial
proteins, including several involved in the electron transport chain, as
well as hemoglobin, and creatine kinase B inmyelin preparations [37–
41]. However, this is the ﬁrst time that myelin basic protein has been
observed associated with mitochondrial fractions. In addition, we see
an increase in the amount of MBP associated with mitochondrial
fractions in MS donors relative to controls by Western blot and have
also shown that the expression of MBP isoforms is altered in the EAE
mouse model of MS. These data suggest that MBP can be localized and
associated with mitochondria both in normal and diseased brain, but
the signiﬁcance of this for MS disease pathology is not clear.
Peptide ﬁngerprint mapping identiﬁed the protein isolated from
fraction 3 of cohort 1 in the 10 kDa region as COX5b, a component of
Complex IV of the electron transport chain. The expression of this
subunit has also been shown to be decreased by mRNA expression
microarray analysis [14]. Nuclear encoded mitochondrial proteins,
including subunit 5b, are transcribed with a positively charged N-
terminal signal sequence which is cleaved upon import into the
appropriate mitochondrial location. The full length COX5b has a
molecular weight of 13,696 Da and a pI of 9.07. However, upon
removal of the 31 residue transit sequence, the molecular weight is
reduced to 10,613 Da and the pI decreases to 6.33. Both physical
properties are in strong agreement with the differentially expressed
species in fraction 3 (5.0–7.0). The loss of this subunit may play a role
in mitochondrial dysfunction since the nuclear encoded subunits
function in the assembly andmaintenance of Complex IV [42]. Indeed,
in null yeast mutants of subunit 4, 5a, 5b, 6c and 7a, Complex IV failed
to assemble [43]. Additionally, Complex IV dysfunction may impact
the production of free radicals, since it has been shown that various
cytochrome c oxidase subunits provide protection from highly
reactive peroxynitrite [44].
Our differential protein expression analysis of mitochondrially
enriched fractions from MS and control gray matter also demonstrated
that the differentially expressed protein in fraction 4 from cohort 2,with
a mass of 16 kDa, was consistent with hemoglobin-β. Notably, both
hemoglobin-α2 and hemoglobin-β genes are upregulated in mononu-
clear blood cells from MS patients as reported recently in a study
comparing monozygous twins discordant for multiple sclerosis [45].
This phenomenon appears to be extended to the brain, since our data
show increased expression of hemoglobin-β in MS cortex. Further, we
localized hemoglobin expression to pyramidal neuronal cell bodies by
immunoﬂuorescent staining with antibodies to both hemoglobin and
neuroﬁlament. The discovery of hemoglobin expression in neurons,
until recently considered speciﬁc to red blood cells, is novel. Other
recent studies support ourﬁnding, including studies byBiagoli et al. [46]
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Table 3
Nitrotyrosine modiﬁed proteins.
UniProt
accession
UniProt entry
name
%
Coverage
Probability Mascot
score
Peptides
detected
Theoretical
MWa
pIb Total tyr
residues
tyr Location in detected
peptides
P02686-3 MBP1c 39.1 2.82E-07 100.2 10 21493 11.3 5 15, 154
P02686-5 MBP3c 45.0 2.82E-07 100.2 10 18590 11.4 4 15, 128
P51970 NDUA8 15.2 6.44E-05 20.2 3 18857 6.7 3 141
P19404 NDUV2 6.45 3.29E-03 20.1 5 223760 5.7 8 NONE
P00403 COX2 15.9 2.37E-04 30.19 3 25550 4.7 9 85
P60709 ACTB 19.5 1.67E-05 50.21 5 41775 5.3 15 90, 197, 293, 305, 361
P12277 CKB 12.4 1.21E-06 30.3 3 42513 5.3 9 NONE
P22695 UQCR2 16.9 2.67E-07 40.23 4 46784 7.7 13 168
P09543 CNPase 15.7 2.28E-07 50.26 5 47578 9.2 14 268
a MW of processed peptide due to signal peptide and/or initiating methioninecleavage.
b pI of processed peptide due to signal peptide or initiating methioninecleavage.
c Human MBP has 7 isoforms. All ten peptides detected by MS/MS are present in the isoforms listed.
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transcripts was shown in dopaminergic neurons from mouse, rat, and
human brains. Functionally, alterations in hemoglobin expression may
affect cellular energetics, since dopaminergic cell lines over expressing
α- and β-globin exhibited changes in oxygen homeostasis and
alterations in the expression of oxidative phosphorylation genes.
These data support our ﬁnding of hemoglobin expression in the brain
and support a potential role for hemoglobin in respiration. Hemoglobin
may also aid in protecting neurons from oxidative damage, since the
ability of hemoglobin α2β2 to scavenge peroxynitrite (ONOO−) in a
variety of O2 bound states has been suggested [48].
Lastly, in cohort 2 we identiﬁed a protein from fraction 6 as
creatine kinase B (42 kDa). It has been observed previously that IgG
from MS patients reacts with hemoglobin β, as well as with creatine
kinase B and the expression of creatine kinase B has also been found in
CSF of MS patients [49,50]. In myocardial infarction, serum levels of
creatine kinase are used as an indicator of heart muscle damage. In
MS, it may represent a similar marker for nervous tissue damage.
However, we detected an almost 2 fold increase in expression in
mitochondrial fractions obtained from nonlesion MS cortex. At this
time, the signiﬁcance and mechanistic importance of these ﬁndings
are not clear. However, in neurons it has been suggested that creatine
kinase Bmay serve to buffer ﬂuctuations in ATP and levels of inorganic
phosphate, as well as serve as a shuttle for high energy phosphate
bonds between mitochondria and cytoplasm [51].
Mitochondrial dysfunction and neuroinﬂammation contribute to
neuropathology not only in MS [52], but are also common to other
complex neurodegenerative diseases such as Alzheimer's disease
(AD) and Parkinson's disease (PD) [53–57]. Additionally, several
studies suggest that mitochondrial dysfunction is an early occurrence
in neurodegeneration and molecular studies have found evidence of
mutant proteins interacting with and preventing transport of nuclear
encoded proteins to mitochondria [58]. Consistent with our ﬁndings
in this study and in previous studies [13,14], the expression of
mitochondrial electron transport chain proteins has also been shown
to be decreased in PD in the brain with Complex I most consistently
reported [59–61]. In contrast, in AD, fewer mitochondria but
increased cytochrome c oxidase (Complex IV) and mitochondrial
DNA have been observed in neurons [62]. In AD, reactive oxygen
species (ROS) may be a primary event mediating mitochondrialFig. 4. Increased immunoﬂuorescent hemoglobin staining in MS parietal cortex pyramidal
postmortem tissue. Micrographs are from control (left column) and MS (right column) postm
(middle row). Hemoglobin can be seen to be localized in a number of neurons, denoted by w
row displays the 2 channels overlayed with the organization of the pyramidal cell layers c
matter from control andMS parietal cortex. Control (row 1) andMS (row 2) tissue sections w
acquired from the pyramidal cell layer using a 60× oil objective and identical acquisition pa
with the reported SELDI-TOF-MS results. The third column depicts the hemoglobin (red ﬂuo
hemoglobin ﬂuorescence within pyramidal cell somas. The scale bar represents 100 μm.dysfunction [63] whereas in PD, a defect inmitochondriamaymediate
increased ROS as mitochondrial toxins can elicit neuronal pathology
similar to PD [64,65]. In MS, mitochondrial damage similar to what
has been reported in both AD and PD has been observed. Damage to
mitochondrial DNA and altered cytochrome c oxidase immunoreac-
tivity similar to what has been observed in AD have been reported in
axons in chronic active and inactive lesions [66,67] while gray matter
pathology in MS is more consistent with PD, including reductions in
electron transport chain subunits and mitochondrial activity [13,14].
While the underlying mechanisms and events involved in mitochon-
drial dysfunction differ between these neurodegenerative diseases,
the end result of thesemitochondrial perturbations is similar resulting
in increased ROS, loss of Ca2+ homeostasis, and necrotic or apoptotic
cell death [68]. In MS these processes are exacerbated by demyelin-
ation which increases energy demand to maintain ion homeostasis
through the energy dependent Na+/K+ ATPase in neurons [69].
Wedetected increasednitration of electron transport chain subunits,
creatine kinase B, and MBP in MS cortex. This is indicative of increased
ROS and peroxynitrite mediated oxidative damage in MS and is
consistent with previous studies [13,70] which reported increased
levels of nitrated proteins in MS tissue when compared with controls.
Nitration of mitochondrial electron transport chain subunits has also
been identiﬁed in AD postmortem brain and in the spinal cord in EAE
[8,71]. Increasedproteinnitration suggests an inﬂammatorymechanism
is involved as inﬂammatory microglial cells express inducible nitric
oxide synthase (iNOS) and release nitric oxide (NO) in MS lesions
[72,73]. This NO can diffuse and react with superoxide formed as a
byproduct of mitochondrial respiration and create peroxynitrite which
can also diffuse through tissue [74] and may account for our ﬁnding
increased protein nitration even in NAGM in MS [13]. Alternatively,
electron transport chainproteinsmaybeoxidativelymodiﬁed asa result
of axonal transport through lesioned axonal segments. Either direct
nitration of electron transport chain proteins by peroxynitrite or
competitive inhibition of electron transport chain Complex IV by NO
can lead to mitochondrial dysfunction [75,76].
5. Conclusions
Our data suggest that alterations in MBP expression and protein
nitration in MS cortex involve an inﬂammatory mechanism sharedcell layer. A. Confocal images taken at 20× of hemoglobin staining in control and MS
ortem tissue sections stained for hemoglobin (Hbb) (top row) and neuroﬁlament (NF)
hite arrows, including pyramidal cells, colocalized with the neuroﬁlament stain. The last
learly visible. B. Images are z-projected multichannel confocal micrographs from gray
ere stained for neuroﬁlament (column 1) and hemoglobin (column 2), and image stacks
rameters. Note increased hemoglobin staining intensity in the MS sample in agreement
rescence) and neuroﬁlament (green ﬂuorescence) data overlayed, and clearly displays
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disease model, in which lesions similar to those observed in MS are
observed upon immunization with myelin protein antigens. This
model has been helpful in understanding inﬂammatory disease
mechanisms in MS but does not reﬂect all aspects of MS neuropa-
thology [77]. MS is both an autoimmune and a neurodegenerative
disease, and while protein nitration and altered MBP expression are
consistent in the EAE mouse model and in MS, we did not observe
similar alterations in expression levels of COX5b, hemoglobin β chain,
or creatine kinase B in EAE, indicating that a separate mechanism is
also involved in MS pathology. This mechanism may involve cellular
stress separate from that mediated by neuroinﬂammation such as
metabolic stress which can lead to differential expression of
mitochondrial enzymes and subunits of the electron transport chain
[78]. The existence of separate mechanisms involved in mitochondrial
dysfunction is not surprising given the heterogeneity and complexity
of MS pathology [79] and is reﬂected in the disparate types of
mitochondrial abnormalities reported in acute and chronic white
matter lesions, in axons, and in gray matter in MS. Increased
mitochondrial density and either increased Complex IV activity or
protein has been reported in chronic active white matter lesions in
axons and astrocytes [12,66] and also in a subset of demyelinated
axons in chronic inactive lesions [67]. In contrast, decreased Complex
IV activity and decreased immunoreactivity to Complex IV subunits
have been reported in acute white matter lesions [10] and also in
injured axons in chronic active lesions [67]. These studies suggest an
adaptive response by both neurons and glia to increase mitochondrial
activity in response to demyelination, thereby increasing ROS, and
also a defect in mitochondrial transport in damaged tissue. Our data
however, examined NAGM rather than lesioned tissue and has
conﬁrmed our previous studies which found decreased expression
of mitochondrial electron transport chain subunit genes in MS [13,14]
and has extended these ﬁndings and implicated an imbalance in the
regulation of additional respiratory proteins in MS disease pathology.
Our ﬁndings have important implications for the development of new
neuroprotective therapies for MS.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2011.01.012.
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